Literature DB >> 7760001

C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation.

P J Daffern1, P H Pfeifer, J A Ember, T E Hugli.   

Abstract

Inflammatory action of the potent chemotaxin C5a has been well characterized on a variety of human cell types, including neutrophils, monocytes, basophils, and eosinophils. The cellular effects of C3a are less well defined. Contradictory reports have been published for C3a activation of neutrophils. Recent reports that C3a activates both basophils and eosinophils prompted us to reinvestigate the effects of C3a stimulation on eosinophils. We hypothesized that C3a activation of eosinophils, cells that are present in most neutrophil preparations, might lead to neutrophil activation. Using neutrophils of 98% purity, we observed no evidence of cellular activation after stimulation with either C3a, recombinant human C3a (rhC3a), or the synthetic C3a analogue C3a 57-77, Y57. Eosinophils purified to > 98% purity displayed concentration-dependent polarization, chemotaxis, and enzyme release by stimulation with C3a, rhC3a, and the synthetic C3a analogue. An inactive form of C3a, C3adesArg, failed to stimulate either eosinophils or neutrophils. Using neutrophil preparations containing 5-9% eosinophils, up to 20% of neutrophils became polarized after exposure to C3a. Likewise, we demonstrated that supernatant from C3a-stimulated eosinophils promotes neutrophil chemotaxis. Eosinophil polarization experiments were repeated in the presence of antibody to the C5a receptor (C5aR) to show that C3a and C5a interact with different receptors. C3a activates eosinophils in the presence of anti-C5aR antibody at concentrations that fully block C5a activation. We conclude that eosinophils are directly activated by either C3a or C5a, whereas C3a failed to activate neutrophils. C3a acts on eosinophils via a receptor that is distinct from C5aR. Since neutrophils are indirectly stimulated by C3a, eosinophils contaminating neutrophil preparations may explain earlier reports that C3a activates human neutrophils.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7760001      PMCID: PMC2192052          DOI: 10.1084/jem.181.6.2119

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  54 in total

1.  An enzyme in human blood plasma that inactivates bradykinin and kallidins.

Authors:  E G ERDOS; E M SLOANE
Journal:  Biochem Pharmacol       Date:  1962-07       Impact factor: 5.858

Review 2.  Anaphylatoxins: C3a and C5a.

Authors:  T E Hugli; H J Müller-Eberhard
Journal:  Adv Immunol       Date:  1978       Impact factor: 3.543

3.  Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro and under stimulated in vivo conditions.

Authors:  H N Fernandez; P M Henson; A Otani; T E Hugli
Journal:  J Immunol       Date:  1978-01       Impact factor: 5.422

4.  A rapid one-step procedure for purification of mononuclear and polymorphonuclear leukocytes from human blood using a modification of the Hypaque-Ficoll technique.

Authors:  A Ferrante; Y H Thong
Journal:  J Immunol Methods       Date:  1978       Impact factor: 2.303

5.  Motility and adhesiveness in human neutrophils. Effects of chemotactic factors.

Authors:  C W Smith; J C Hollers; R A Patrick; C Hassett
Journal:  J Clin Invest       Date:  1979-02       Impact factor: 14.808

6.  Effects of corticosteroids on eosinophil chemotaxis and adherence.

Authors:  L C Altman; J S Hill; W M Hairfield; M F Mullarkey
Journal:  J Clin Invest       Date:  1981-01       Impact factor: 14.808

7.  Optimal conditions for simultaneous purification of mononuclear and polymorphonuclear leucocytes from human blood by the Hypaque-Ficoll method.

Authors:  A Ferrante; Y H Thong
Journal:  J Immunol Methods       Date:  1980       Impact factor: 2.303

8.  Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase.

Authors:  V A Bokisch; H J Müller-Eberhard
Journal:  J Clin Invest       Date:  1970-12       Impact factor: 14.808

9.  Anaphylatoxin-induced histamine release with human leukocytes: studies of C3a leukocyte binding and histamine release.

Authors:  M M Glovsky; T E Hugli; T Ishizaka; L M Lichtenstein; B W Erickson
Journal:  J Clin Invest       Date:  1979-09       Impact factor: 14.808

10.  Aggregation of leukocytes induced by the complement-derived peptides C3a and C5a and by three synthetic formyl-methionyl peptides.

Authors:  B Damerau; E Grünefeld; W Vogt
Journal:  Int Arch Allergy Appl Immunol       Date:  1980
View more
  58 in total

Review 1.  Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis.

Authors:  J E Salmon; G Girardi; V M Holers
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

Review 2.  Evolution of complement as an effector system in innate and adaptive immunity.

Authors:  J Oriol Sunyer; Hani Boshra; Gema Lorenzo; David Parra; Bruce Freedman; Nina Bosch
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

3.  Mast cell anaphylatoxin receptor expression can enhance IgE-dependent skin inflammation in mice.

Authors:  Beatrix Schäfer; Adrian M Piliponsky; Tatsuya Oka; Chang Ho Song; Norma P Gerard; Craig Gerard; Mindy Tsai; Janet Kalesnikoff; Stephen J Galli
Journal:  J Allergy Clin Immunol       Date:  2012-06-22       Impact factor: 10.793

Review 4.  Complement activation in the context of stem cells and tissue repair.

Authors:  Ingrid U Schraufstatter; Sophia K Khaldoyanidi; Richard G DiScipio
Journal:  World J Stem Cells       Date:  2015-09-26       Impact factor: 5.326

5.  Identification of ligand effector binding sites in transmembrane regions of the human G protein-coupled C3a receptor.

Authors:  J Sun; J A Ember; T H Chao; Y Fukuoka; R D Ye; T E Hugli
Journal:  Protein Sci       Date:  1999-11       Impact factor: 6.725

Review 6.  The role of the anaphylatoxins in health and disease.

Authors:  Andreas Klos; Andrea J Tenner; Kay-Ole Johswich; Rahasson R Ager; Edimara S Reis; Jörg Köhl
Journal:  Mol Immunol       Date:  2009-05-28       Impact factor: 4.407

7.  Evidence for complement activation in the amniotic fluid of women with spontaneous preterm labor and intra-amniotic infection.

Authors:  Eleazar Soto; Roberto Romero; Karina Richani; Bo H Yoon; Tinnakorn Chaiworapongsa; Edi Vaisbuch; Pooja Mittal; Offer Erez; Francesca Gotsch; Moshe Mazor; Juan P Kusanovic
Journal:  J Matern Fetal Neonatal Med       Date:  2009-11

Review 8.  Functional role of eosinophils in gastrointestinal inflammation.

Authors:  Simon P Hogan
Journal:  Immunol Allergy Clin North Am       Date:  2009-02       Impact factor: 3.479

9.  Preeclampsia and pregnancies with small-for-gestational age neonates have different profiles of complement split products.

Authors:  Eleazar Soto; Roberto Romero; Karina Richani; Jimmy Espinoza; Tinnakorn Chaiworapongsa; Jyh Kae Nien; Sam S Edwin; Yeon Mee Kim; Joon Seok Hong; Luis F Goncalves; Lami Yeo; Moshe Mazor; Sonia S Hassan; Juan Pedro Kusanovic
Journal:  J Matern Fetal Neonatal Med       Date:  2010-07

10.  Serum amyloid A, properdin, complement 3, and toll-like receptors are expressed locally in human sinonasal tissue.

Authors:  Andrew P Lane; Quynh-Ai Truong-Tran; Allan Myers; Carol Bickel; Robert P Schleimer
Journal:  Am J Rhinol       Date:  2006 Jan-Feb
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.